

CURRICULUM VITAE

KARÉN MATEVOSYAN, MD

The University of Texas Southwestern Medical Center
Department of Pathology
5323 Harry Hines Blvd, suite CS3.114, Dallas, Texas 75390-9073
tel.: (214) 648-7886 (office); fax: (214) 648-8037
e-mail: Karen.Matevosyan@UTSouthwestern.edu

EDUCATION:

Medical Education:

1975–1981 **Doctor of Medicine**, Azerbaijan State Medical University, Baku, Azerbaijan

Postgraduate Education:

1981-1982 **Internship in Pediatrics**, No. 8 Municipal Children’s Hospital, Baku, Azerbaijan

2003-2006 **Residency in Clinical Pathology**, the University of Texas Southwestern Medical Center at Dallas, TX

2006-2008 **Fellowship in Transfusion Medicine**, University of Texas Southwestern Medical Center at Dallas, TX

Honors and Awards

1982 Internship Certificate with Highest Distinction, Azerbaijan State Medical University, Baku, Azerbaijan

CERTIFICATION AND LICENSURE:

Diplomate, American Board of Pathology:

8/04/2010 ***Clinical Pathology***

9/14/2011 ***Blood Banking/Transfusion Medicine***

Certificate:

12/04/2002 ***Educational Commission for Foreign Medical Graduates***

Licensure (active):

12/15/2010-Present ***Texas Medical Board - License No. N8319***

3/16/2009-Present ***Commonwealth of Pennsylvania*** (Medical Physician and Surgeon) - ***License No. MD436625***

CURRICULUM VITAE

KARÉN MATEVOSYAN, MD

PROFESSIONAL SOCIETIES (Member):

2004-2008	American Society of Clinical Pathology
2004-Present	American Society for Apheresis
2004-Present	College of American Pathologists
2005-Present	North Texas Society of Pathologists
2007-Present	American Society of Hematology
2008-Present	American Association of Blood Banks

PROFESSIONAL APPOINTMENTS:

Faculty Academic Appointments

2008-present	Assistant Professor , Department of Pathology, University of Texas Southwestern Medical Center at Dallas, TX
--------------	---

Appointments at Hospitals/Affiliated Institutions

Current

2008-2010	Assistant Director , Transfusion Medicine and Hemostasis Reference Laboratory, University of Texas Southwestern Medical Center at Dallas, TX
2010-present	Associate Director , Transfusion Medicine and Hemostasis Reference Laboratory, University of Texas Southwestern Medical Center at Dallas, TX
2010-present	Medical Director , Therapeutic Apheresis, University of Texas Southwestern Medical Center at Dallas, TX

Past

1982-1988	Staff Pediatrician , Emergency Room, Children's City Hospital, Sumgait, Azerbaijan
1988-1991	Staff Pediatrician , Pediatric Intensive Care, No. 3 Children's Hospital, Yerevan, Armenia
1992-1993	Phlebotomist , Associate Regional and University Pathologists, Inc., Salt Lake City, UT
1992-1993	Medical Interpreter , Salt Lake City / County Health Department, Salt Lake City, UT

CURRICULUM VITAE

KARÉN MATEVOSYAN, MD

1993-2003 **Apheresis Specialist**, Parkland Health & Hospital System, Dallas County Hospital District, Dallas, TX

Hospital Privileges:

2008-Present University Hospitals – University of Texas Southwestern Medical Center at Dallas, TX (full privileges)
2008-Present Parkland Health & Hospital System, Dallas County Hospital District, Dallas, TX (full privileges)
2008-Present Children’s Medical Center at Dallas (consultant in therapeutic apheresis)
2011-Present Veterans Administration North Texas Health Care System, Dallas, TX (Research consultant)

Hospital Committee Memberships:

2004–Present **Blood Utilization Review Committee** (Committee meets bi-monthly)
Member representing Transfusion Medicine, Parkland Health & Hospital System, Dallas County Hospital District, Dallas, TX.
2005-Present **Blood Utilization Review Committee** (Committee meets quarterly)
Member representing Transfusion Medicine, University Hospitals, University of Texas Southwestern Medical Center at Dallas, TX.

TEACHING ACTIVITIES:

2008- Present Department of Pathology, *University of Texas Southwestern Medical Center at Dallas, Dallas, Texas*

- Daily didactic teaching to Pathology residents and Blood Bank/Transfusion Medicine fellows
- Sophomore Pathology Course: small group facilitator
- Sophomore Pathology Course: Course Lecturer - Introduction to Hemostasis

Selected Lectures:

2005 “Death Defying Immunity” *Extracorporeal Photopheresis in the Management of Solid Organ Transplant Rejection. Pathology Grand Rounds - Updates in Pathophysiology*
2006 *Acquired Hemophilia. Pathology Grand Rounds - Updates in Pathophysiology*
2011 *Therapeutic Plasma Exchange in Renal Pathology. Nephrology Fellowship Program. UT Southwestern.*
2011 *Therapeutic Apheresis – Principles and Practice. Faculty Lecture. Hematology/Hematopathology Rounds. UT Southwestern.*

CURRICULUM VITAE

KARÉN MATEVOSYAN, MD

RESEARCH ACTIVITY:

- 2011-Present *Evaluation of the Effect of Therapeutic Plasma Exchange in the Management of Neuromyelitis Optica*
- 2011-Present *Ablynx NV. Phase II, single-blind, randomized, placebo-controlled trial to study the efficacy and safety of anti-von Willebrand factor nanobody administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura. Co-investigator.*
- 2011-Present *Plaque Regression and Progenitor Cell Mobilization with Intensive Lipid Elimination Regimen (PREMIER). VAMC. Role: Co-investigator.*
- 2010-Present *Can HIT be ruled out by a low 4T score without testing? Co-investigator.*
- 2008-2010 *Whole Blood Platelet Aggregation Assay: Clinical Correlation with Hyperactive Platelet Syndrome and Primary Platelet Dysfunction.*
- 2006-2011 *Trauma Coumadin Protocol: Use of Prothrombin Complex Concentrate and Recombinant Factor VIIa in patients on warfarin and with head or torso trauma. Study coordinator.*
- 2003-2011 *Isovolemic Hemodilution Red Cell Exchange for Prevention of Stroke in Sickle Cell Disease Patients. Co-investigator*
- 2007-2008 *HIT Observational Thromboembolism Study (Transfusion Medicine/Hemostasis Clinical Trials Network multicenter study). Study coordinator.*
- 2005-2005 *Correlation between optical densities of Heparin-Platelet factor 4 ELISA assay and clinical thrombosis in patients with Heparin-induced thrombocytopenia. Study coordinator.*
- 2003-2004 *Correlation between clotting factors II, VII and VIII levels and isolated, mild increase in INR (1.3-1.7) in neurosurgical patients. Study coordinator.*

KARÉN MATEVOSYAN, MD

PUBLICATIONS:**Peer-reviewed publications:**

1. Refaai MA, Warkentin TE, Axelson M, **Matevosyan K** and R Sarode. Delayed-Onset Heparin-Induced Thrombocytopenia, Venous Thromboembolism, and Cerebral Venous Thrombosis: A Consequence of Heparin "Flushes". *Thromb Haemost*, 2007;98:1139-1140.
2. F Altuntas, **Matevosyan K**, YM Shen, J Burner, R Sarode. Higher Optical Density of an Antigen Assay Predicts Thrombosis in Patients with Heparin Induced Thrombocytopenia. *Eur J Hematol*, 2008;80:429-435.
3. Park YA, Hay SN, King KE, **Matevosyan K**, Poisson J, Powers A, Sarode R, Shaz B, Brecher M. Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy. *J Clin Apher*. 2009;24:115-9.
4. Sarode R, Refaai MA, **Matevosyan K**, Burner JD, Hampton S, Rutherford C. Prospective Monitoring of Plasma and Platelet Transfusions in a Large Teaching Hospital Results in Significant Cost Reduction. *Transfusion*. 2010 Feb;50(2):487-92. Epub 2009 Oct 5. PMID: 19804569
5. **Matevosyan K**, Madden C, Barnett SL, Beshay J, Rutherford C, Sarode R. Coagulation factor levels in neurosurgical patients with mild prolongation of prothrombin time: Effect on plasma transfusion therapy. *J Neurosurg*. Sept 3, 2010; DOI: 10.3171/2010.7.JNS091699 (PMID: 20815699). *J Neurosurg*. Jan 11, 2011;114(1):3-7.
6. Bhagat R, **Matevosyan K**, Jones R, Vetus ML, Burner JD, Sarode R. Rinseback during red blood cell exchange with COBE Spectra does not affect fraction of cells remaining (FCR) or post-exchange hematocrit. *J Clin Apher*, 2010;25(6):347-9
7. Sarode R, **Matevosyan K**, Rogers Z, Burner J, Rutherford C. "Advantages of Isovolemic Hemodilution-Red Cell Exchange Therapy to Prevent Recurrent Stroke in Sickle Cell Anemia Patients". *J Clin Apher*. 2011 Jul 22. DOI: 10.1002/jca.20294. [Epub ahead of print]
8. Sarode R, **Matevosyan K**, Bhagat R, Beshay J, Rutherford C, Madden C. Rapid Warfarin Reversal: A Three-factor Prothrombin Complex Concentrate and Recombinant Factor FVIIa Cocktail for Intracranial Hemorrhage. *J Neurosurg*. 2011. DOI: 10.3171/2011.11JNS11836.

Non-peer reviewed scientific/medical publications:

1. **Matevosyan K**. Check Sample: Use (and Misuse) of Plasma in Clinical Practice. *Transfusion Medicine*. Vol. 50; No. TM 07-1 (TM-293); ISSN 1056-5949. *ASCP Press*. January 2007.

Peer-reviewed works - In Press:

1. **Matevosyan K**, Anderson C, Sarode R. Isovolemic Hemodilution-Red Cell Exchange for Prevention of Cerebrovascular Accident in Sickle Cell Anemia - the Standard Operating Procedure. *J Clin Apher*. 2011.

CURRICULUM VITAE

KARÉN MATEVOSYAN, MD

Peer-reviewed works - Submitted for Publication:

1. Prapti Patel, Yu-Min Shen, **Karen Matevosyan**, Eugene Frenkel, Ravi Sarode. Autoimmune Severe Acquired von Willebrand Syndrome (type 3-like) – successful treatment with rituximab. *Hemophilia*. 2011

Editorials:

1. Sarode R, **Matevosyan K**. Prothrombin complex concentrate and fatal thrombosis: poor evidence to implicate a relatively safe drug. *Ann Emerg Med*. 2009;54:481-2.
2. **Matevosyan K**, Madden C, Barnett SL, Beshay J, Rutherford C, Sarode R. Response to Editorial by Hoffer A and Selman W. Transfusion. *J Neurosurg*. Sept 3, 2010; DOI: 10.3171/2010.6.JNS10436. *J Neurosurg*. Jan 11, 2011;114(1):1-2.

Selected Abstracts and Presentations:

1. **Matevosyan K**, Anderson C, Schellhase R, Vetus ML, Jones R, Reagans M, Paranjape G, Sarode R. Impact of Variation of Hematocrits of RBC Units on the End Hematocrits during RBC Exchange Procedures. *J Clin Apher*, 2003;18(2):90. (Platform presentation at 24th Annual Meeting of American Society for Apheresis, May 2003. Lake Tahoe, NV)
2. Paranjape G, Rawal A, Anderson C, Rogers Z, Sartwell C, Wood L, **Matevosyan K**, Sarode R. Isovolemic Hemodilution - Red Cell Exchange (IHD-RBC X) in Sickle Cell Disease - a Follow Up. *Journal of Clinical Apheresis*, Vol.18, number 2, 2003, page 92, abstract #37.
3. **Matevosyan K**, Cimo M, Madden C, Sarode R. Hemostatic Levels of Coagulation Factors in Patients with Isolated Prolongation of Prothrombin Time / INR: Implications for Transfusion Medicine Practice. *Blood*. 2004;104(11):745a. (46-th Annual Meeting of the American Society of Hematology. San Diego, CA. December 5, 2004. [poster presentation])
4. **Matevosyan K**, Alsammak MS, Sarode R. Extracorporeal Photopheresis in the Management of Heart Transplant Rejection. *J Clin Apher*. 2005;20(1):19. (26th Annual Meeting of American Society for Apheresis, Chicago, IL. April 29, 2005. [Platform presentation])
5. Altuntas F, **Matevosyan K**, Burner J, Rutherford C, Sarode R. Lack of Correlation between OD Value of ELISA and Clinical Thrombosis in Patients with Heparin Induced Thrombocytopenia (HIT). *Journal of Thrombosis and Haemostasis*; Volume 3, Supplement 1, August 2005, abstract #P0319
6. **Matevosyan K**, Altuntas F, Burner J, Sarode R. Transfusion Medicine: Analysis of Resident Calls. American Association of Blood Banks. *Transfusion*. 2005;45(sp3):409. (2005 Annual Meeting and TXPO. October 15-18 2005, Seattle, WA. [Poster presentation])
7. **Matevosyan K**, Vetus ML, R. Jones, E. George, R. Sarode, Extracorporeal Immunoabsorption (Immunosorba) for Treatment of refractory Acquired Hemophilia A (Factor VIII Inhibitor): Case Report. *J Clin Apher*. 2007;22(2):63-64. (28th ASFA Annual Meeting, April 18-21, 2007, Nashville, TN [Platform presentation])

CURRICULUM VITAE

KARÉN MATEVOSYAN, MD

8. Stalos S, **Matevosyan K**, El Sharif M, Burner J, Sarode R. Therapeutic response to plasmapheresis in patients with Devic's syndrome (Disease) and multiple sclerosis with optic neuritis.
9. **Matevosyan K**, Madden C, Aung F, Chason D, Arbique G, Guild J, Shafi S, Sarode R. Management of Warfarin Associated Intracranial Hemorrhage with a 3-factor Prothrombin Complex Concentrate and low dose Recombinant Factor VIIa. *Blood*, 2008;112(11):1165 (50th Annual Meeting of American Society of Hematology. San Francisco, Dec 4-9, 2008 [Poster presentation]).
10. **Matevosyan K**, Cleveland-Noriega DS, Burner JD, Sarode R. Management of Therapeutic Plasma Exchange-associated Dilutional Hypofibrinogenemia. *J. Clin. Apheresis*. 2009;68-69. (30th ASFA Annual Meeting, April 18-21, 2009, San-Diego, CA [Platform Presentation]).
11. Dava S. Cleveland-Noriega, **Karen Matevosyan**, James Burner, Majed Refaai, Ravi Sarode. Efficacy of Dual Lumen Implantable Vortex Ports During Isovolemic Hemodilution/Red Blood Cell Exchange in Sickle Cell Disease Patients. *J. Clin. Apheresis*. 2009;24:64
12. Dava S. Cleveland-Noriega, **Karen Matevosyan**, James Burner, Ravi Sarode. Septic Shock With Multiorgan Dysfunction Syndrome (Mods) Successfully Treated With Therapeutic Plasma Exchange. *J. Clin. Apheresis*. 2009;24:88
13. Mahaldar A, Shen YM, **Matevosyan K**, Burke C, Frenkel E, Sarode R. Efficacy of Whole Blood Impedance Aggregometry (WBIA) in Identifying Platelet Abnormalities Relevance in Bleeding Patients. XXII Congress of the International Society on Thrombosis and Haemostasis. July 11-16, 2009 (Poster Presentation).
14. Patel PA, Burke C, **Matevosyan K**, Frenkel EP, Sarode, R and Shen YM. Low Risk 4T Score Can Rule out Heparin-Induced Thrombocytopenia. 2009 ASH Annual Meeting Abstracts. *Blood*, 2009;114(22):542, abstract #1328
15. Ziari M, Burke C, **Matevosyan K**, Frenkel EP, Sarode, R and Shen YM. Optical Density of 1.0 is a Better Cutoff for Positive HIT Ab ELISA. 2009 ASH Annual Meeting Abstracts. *Blood*, 2009;114(22):1363, abstract #3515
16. Navarro A , **Matevosyan K**, MD, Cleveland DS, Sarode R. Cryoprecipitate vs plasma in the management of dilutional hypofibrinogenemia in patients undergoing therapeutic plasma exchange. *J Clin Apher*, 2010; 25:7.
17. Shah N, Yamani F, **Matevosyan K**, Rutherford C, Shen Y-M, Neunert C, Sarode R. ADAMTS13 Distinguishes Thrombotic Thrombocytopenic Purpura (TTP) from Other Forms of Thrombotic Microangiopathies. *J Clin Apher*, 2011; 26(2):66.
18. De Simone N, Malbrough R, Filiberto D, Inocando J, Burner J, **Matevosyan K**, Sarode R. Routine Prophylactic Intravenous Calcium Supplementation to Prevent Citrate Reactions During Plasma Exchange is not Indicated. *J Clin Apher*, 2011; 26(2):67.

CURRICULUM VITAE

KARÉN MATEVOSYAN, MD

Volunteer activities

- 1995-2002 Volunteer Medical Interpreter (Russian, Armenian). Parkland Memorial Hospital, Dallas, TX.
- 2006 "Open World" project: "Medical Care in North Texas". Carter-Blood Care, Co-host and interpreter for visiting Russian physicians. Bedford, TX.

Personal

- Citizenship: USA
- Languages: Russian (fluent - read/write/speak); Armenian (colloquial), Azerbaijani-Turkish (colloquial)
- Personal interests: History, ethnography, linguistics, fine arts, jazz and classical music

CURRICULUM VITAE

KARÉN MATEVOSYAN, MD

REFERENCES:

Ravindra Sarode, M.D.

Director, Transfusion Medicine and Hemostasis Laboratory
Professor of Pathology
University of Texas Southwestern Medical Center at Dallas
5323 Harry Hines Blvd.
CS 3.114
Dallas, TX 75390-9073
Phone: (214) 648-7887
Fax: (214) 648-8037
e-mail: ravi.sarode@utsouthwestern.edu

James D. Burner, M.D.

Associate Director, Transfusion Medicine and Hemostasis Laboratory
Assistant Professor of Pathology
University of Texas Southwestern Medical Center at Dallas
5323 Harry Hines Blvd.
CS 3.114
Dallas, TX 75390-9073
Phone: (214) 648-9198
Fax: (214) 648-8037
e-mail: james.burner@utsouthwestern.edu

M. Qasim Ansari, M.D.

Professor and Director, Clinical Pathology
University of Texas Southwestern Medical Center at Dallas
5323 Harry Hines Blvd.
CS 3.114
Dallas, TX 75390-9073
Phone: (214) 648-7885
Fax: (214) 648-8037
e-mail: qasim.ansari@utsouthwestern.edu

Geeta S. Paranjape, M.D.

Medical Director, Clinical Services
Carter BloodCare, Inc.
Assistant Professor of Pathology
2205 Highway 121
Bedford, TX 76021
Phone: (817) 412-5612
Fax: (817) 412-5991
e-mail: gparanjape@carterbloodcare.org